Liquid Biopsy Diagnostics Market is expected to reach USD 14.4 billion by 2031

Liquid Biopsy Diagnostics Market Trends & Forecast

According to a research study published by Knowledge Sourcing Intelligence (KSI), the liquid biopsy diagnostics market will expand from USD 6.4 billion in 2026 to USD 14.4 billion in 2031 at a CAGR of 17.6% during the forecast period.

The liquid biopsy diagnostics industry is witnessing rapid development owing to increasing cancer diagnoses, a rise in demand for minimally invasive techniques, and improvements in molecular biology and genomic technologies. Liquid biopsy means the study of tumor-derived elements like circulating tumor DNA (ctDNA), circulating tumor cells (CTCs), exosomes, and other biomarkers obtained from body fluids such as blood, urine, or saliva, thereby providing a less invasive alternative to conventional tissue biopsies. Besides, the market is stimulated by factors such as increasing use of personalized medicine, rising patient and healthcare provider awareness, and supportive regulatory changes leading to quick approval of innovative diagnostic tests.

Request a free sample copy or view the report summary: Liquid Biopsy Diagnostics Market Report

Liquid Biopsy Diagnostics Market Report Highlights

• Kits & Reagents, among the different product type segments, will likely be the fastest-growing segment in the liquid biopsy diagnostics market. Their continuous use in diagnostic procedures is the main reason for this increase, as they are necessary components of every test. Since liquid biopsy tests are being increasingly conducted in hospitals, diagnostic labs, and research centers, the need for ready-to-use reagents is also growing. These kits have been tailored to enhance sensitivity and accuracy in the detection of very low levels of biomarkers such as ctDNA and CTCs, which is very important for early cancer detection and patient monitoring.

• Among the different types of biomarkers, ctDNA is expected to be the fastest-growing segment given its direct clinical significance and wide range of applications across different forms of cancer. ctDNA offers essential genetic details of tumours, which allow mutation detection, monitoring of the disease, and identifying the resistance of tumours to treatment in a non-invasive manner. Since it can show the heterogeneity of tumours and keep up with changes happening in real time, it is very important in precision oncology.

• The technology segment will be experiencing significant changes as Next-Generation Sequencing (NGS) is expected to record the highest growth rate due to its feature to analyze multiple genes at the same time with a very high level of accuracy and depth. NGS makes it possible to do a thorough genomic profiling, which is vital for finding mutations that can be targeted with specific drugs. The falling price of sequencing, along with the enhancement of the throughput and capacity for data analysis, has led to the increased availability of NGS for healthcare professionals.

• Cancer diagnosis is one of the fastest-growing application segments. The main reason behind the growth is an increasing focus on early detection and screening. Liquid biopsy is a non-invasive, safer, and more convenient option of traditional tissue biopsy that is increasing patient compliance and allowing tests to be done more frequently. The worldwide increase in cancer cases and the need for early diagnoses to increase survival rates are major factors improving this segment.

• Among regional segments, North America is expected to be the fastest-growing market for liquid biopsy diagnostics, driven by its advanced healthcare infrastructure, strong presence of leading biotechnology and diagnostics companies, and rapid adoption of innovative technologies.

Liquid Biopsy Diagnostics Market Growth Drivers and Restraints

Growth Drivers:

• Rising Global Cancer Burden: Due to aging of populations, changes in lifestyles, and environmental factors, cancer cases keep on increasing, which creates a high demand for diagnostic tools that are efficient, fast, and accurate. The liquid biopsy method provides a way to detect cancer in a minimally invasive way, which contributes greatly to improved outcomes and survival rates in patients.

• Advancements in Genomic and Molecular Technologies: Technological innovations like next-generation sequencing (NGS), digital PCR, and bioinformatics tools have greatly contributed to the improvement of the sensitivity, specificity, and accuracy of liquid biopsy tests.

Restraints:

• High Cost of Testing and Equipment: One of the major challenges in the liquid biopsy diagnostics market is the high cost associated with advanced technologies such as NGS and digital PCR. These costs include not only the instruments but also reagents, data analysis, and skilled personnel.

Liquid Biopsy Diagnostics Market Key Development

• Product Launch: In September 2025, Myriad Genetics, a player in molecular diagnostics and precision medicine, and SOPHiA GENETICS, revealed a strategic partnership aimed at designing and offering pharma companies a global liquid biopsy companion diagnostic (CDx) test.

• Product Launch: In May 2025, Guardant Health announced major upgrades to its Guardant360 Liquid test. As a result, it has added almost a dozen new intelligent liquid biopsy applications through its Guardant Infinity™ platform. With these new features, doctors can use a single blood sample to identify tumour phenotypes, verify the lack of actionable mutations, sort cancer subtypes, and detect pharmacogenomic markers.

Liquid Biopsy Diagnostics Market Segmentation

Knowledge Sourcing Intelligence has segmented the liquid biopsy diagnostics market based on product type, biomarker type, technology, application, and region:

Liquid Biopsy Diagnostics Market, By Product Type

• Kits & Reagents

• Instruments

• Services

Liquid Biopsy Diagnostics Market, By Biomarker Type

• Circulating Tumor Cells (CTCs)

• Circulating Tumor DNA (ctDNA)

• Extracellular Vesicles (EVs)

• Cell-Free DNA (cfDNA)

Liquid Biopsy Diagnostics Market, By Technology

• Next-Generation Sequencing (NGS)

• Polymerase Chain Reaction (PCR)

• Microarray

• Digital PCR

Liquid Biopsy Diagnostics Market, By Application

• Cancer Diagnosis

• Therapy Selection

• Treatment Monitoring

• Recurrence Monitoring

Liquid Biopsy Diagnostics Market, By Region

• North America

  • USA

  • Canada

  • Mexico

• Europe

  • United Kingdom

  • Germany

  • France

  • Spain

  • Others

• Asia Pacific

  • China

  • India

  • Japan

  • South Korea

  • Indonesia

  • Thailand

  • Others

• South America

  • Brazil

  • Argentina

  • Others

• Middle East and Africa (MEA)

  • Saudi Arabia

  • UAE

  • Others

Liquid Biopsy Diagnostics Market Key Players

• Guardant Health

• Roche Diagnostics

• Illumina

• Thermo Fisher Scientific

• QIAGEN

• Bio-Rad Laboratories

• Exact Sciences

• Freenome

• GRAIL

• Agilent Technologies